De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes

BACKGROUND: De-escalation from potent platelet P2Y12 inhibitors to clopidogrel is common. Despite having a clinical rationale, non-bleeding-related de-escalation when a lateral change between potent agents is an option may put patients at increased ischemic risk. We set out to define the scope of P2...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Quinton, Fu, Angel, Boudreau, Rene, Chow, Alyssa, Clifford, Cole, Simard, Trevor, Chong, Aun Yeong, Dick, Alexander, Froeschl, Michael, Glover, Christopher, Hibbert, Benjamin, Labinaz, Marino, Le May, Michel, Russo, Juan, So, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531228/
https://www.ncbi.nlm.nih.gov/pubmed/34712935
http://dx.doi.org/10.1016/j.cjco.2021.04.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531228/
https://www.ncbi.nlm.nih.gov/pubmed/34712935
http://dx.doi.org/10.1016/j.cjco.2021.04.010

Ejemplares similares